+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Melanocyte Protein PMEL - Pipeline Review, H2 2019

  • PDF Icon

    Drug Pipelines

  • 53 Pages
  • December 2019
  • Region: Global
  • Global Markets Direct
  • ID: 4900268
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Melanocyte Protein PMEL - Pipeline Review, H2 2019

Summary

Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Melanocyte Protein PMEL - Pipeline Review, H2 2019, outlays comprehensive information on the Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Melanocyte protein PMEL also known as premelanosome protein (PMEL) is a protein encoded by the PMEL gene. This protein is involved in generating internal matrix fibers that define the transition from Stage I to Stage II melanosomes. This protein undergoes a complex pattern of posttranslational processing and modification that is essential to the proper functioning of the protein. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 2 respectively. Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Melanoma, Metastatic Melanoma, Glioblastoma Multiforme (GBM) and Uveal Melanoma.

Furthermore, this report also reviews key players involved in Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL)
  • The report reviews Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) targeted therapeutics

Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Introduction
Report Coverage
Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Overview
Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Companies Involved in Therapeutics Development
Cellid Co Ltd
PDC Line Pharma SAS
Scancell Holdings Plc
Vault Pharma Inc
Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Drug Profiles
BVAC-M - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target GP100 for Melanoma and Non Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PDC-mel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCIB-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPI-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Dormant Products
Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Discontinued Products
Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Product Development Milestones
Featured News & Press Releases
Aug 19, 2019: Update on the SCIB1 Phase 2 clinical trial in patients with advanced melanoma
Apr 25, 2019: Scancell announces UK regulatory approval to start SCIB1 phase 2 trial in patients with advanced melanoma
Oct 24, 2018: Scancell and Ichor provide update on SCIB1 Phase 2 clinical study in patients with advanced melanoma
Feb 12, 2018: Peer-reviewed publication highlights potential of SCIB1 therapy for melanoma patients
Aug 29, 2017: Oncimmune and Scancell Present Data on use of Autoantibodies in Predicting Response to SCIB1 Immunotherapy
Jul 11, 2017: Continued progress on SCIB1 - eight patients reach 5 year survival milestone
Jun 26, 2017: Scancell Holdings Announces SCIB1 Patent Granted in Europe
Jan 03, 2017: Final SCIB1 Phase 1/2 Clinical Study Report completed on schedule
Jul 21, 2016: Scancell Holdings Announces Leading DNA plasmid manufacturer Eurogentec appointed to manufacture new SCIB1 material
Jul 06, 2016: SCIB1 continues to deliver compelling survival data in melanoma
Jun 17, 2016: SCIB1 Drug Product Supply
Mar 23, 2016: Scancell's SCIB1 ImmunoBody cancer vaccine being presented at the World Vaccine Congress
Jan 11, 2016: Early Immune Effect of SCIB1 Cancer Vaccine Observed in Blood by ImmunTraCkeR® Companion Diagnostic
Oct 20, 2015: Translating innovative science into ground-breaking new products
Sep 16, 2015: ImmunoBody Presentation at Cancer vaccines Conference in London
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Cellid Co Ltd, H2 2019
Pipeline by PDC Line Pharma SAS, H2 2019
Pipeline by Scancell Holdings Plc, H2 2019
Pipeline by Vault Pharma Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Cellid Co Ltd
  • PDC Line Pharma SAS
  • Scancell Holdings Plc
  • Vault Pharma Inc